利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.041 秒)

    Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use
    2.
    发明申请
    Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use 审中-公开
    猪生殖和呼吸综合征分离物及其使用方法

    公开(公告)号：US20100028860A1

    公开(公告)日：2010-02-04

    申请号：US12548597

    申请日：2009-08-27

    申请人： Michael Roof ,  Eric Vaughn ,  Wesley Johnson

    发明人： Michael Roof ,  Eric Vaughn ,  Wesley Johnson

    IPC分类号： C12Q1/70

    CPC分类号： C12N7/00 ,  C12N2770/10031

    摘要： A method of predicting the virulence of a new or uncharacterized PRRS virus strain is provided wherein the strain is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus strain of known virulence, as a measure of the virulence of the new or uncharacterized strain.

    摘要翻译： 提供了一种预测新型或非特异性PRRS病毒株的毒力的方法，其中将菌株注射到猪中并允许复制约3-15天的时间。 在此期间，确定病毒增长率和/或病毒血症的大小，并将该数据与已知毒力的PRRS病毒株的相应生长速率和/或病毒血症量进行比较，作为毒力 新的或未表征的菌株。

    Lawsonia intracellularis immunological proteins
    3.
    发明申请
    Lawsonia intracellularis immunological proteins 审中-公开
    胞内劳氏菌免疫蛋白

    公开(公告)号：US20080279893A1

    公开(公告)日：2008-11-13

    申请号：US11414764

    申请日：2006-04-28

    申请人： Eric Vaughn ,  Merrill Schaeffer ,  Yajie Liang

    发明人： Eric Vaughn ,  Merrill Schaeffer ,  Yajie Liang

    IPC分类号： A61K39/00 ,  C07K14/00 ,  C12N15/11 ,  C12N15/00 ,  G01N33/569 ,  A61K31/70 ,  A61K38/00

    CPC分类号： C07K14/195 ,  C07K16/12 ,  G01N33/56911 ,  G01N2469/20

    摘要： The present invention provides nucleic acid and amino acid sequences useful as the immunogenic portion of vaccines or immunogenic compositions effective for lessening the severity of the clinical symptoms associated with Lawsonia intracellularis infection or conferring protective immunity to an animal susceptible to such infection. Preferred amino acid sequences are selected from the group consisting of 1) a polypeptide comprising a sequence selected from the group consisting of SEQ ID Nos.: 1-455, SEQ ID No 466, or the polypeptide encoded by SEQ ID No: 456, SEQ ID No: 457 or SEQ ID No: 466; 2) any polypeptide that has at least 85% sequence homology, more preferably at least about 90% sequence homology, still more preferably at least about 95% sequence homology, even more preferably at least about 97% sequence homology, still even more preferably at least about 98% sequence homology, and even more preferably at least about 99% sequence homology to the polypeptide of 1); 3) any immunogenic portion of the polypeptides of 1) and/or 2) 4) the immunogenic portion of 3), comprising at least 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 18, 15, 13, 10, or most preferably 9 contiguous amino acids included in the sequences of SEQ ID No: 1-455, SEQ ID No: 456, or the amino acid sequence encoded by SEQ ID No: 457 or SEQ ID No: 466; and/or 5) a polypeptide that is encoded by a DNA that codes for a peptide comprising the sequence of SEQ ID No: 1-455 or SEQ ID No: 466. Thus, the nucleic acid sequences encoding such proteins, or the proteins themselves are included in vaccine compositions, together with veterinary-acceptable carrier and administered to an animal in need thereof.

    摘要翻译： 本发明提供了可用作疫苗或免疫原性组合物的免疫原性部分的核酸和氨基酸序列，其有效减轻与胞内劳森氏菌感染相关的临床症状的严重性或赋予对这种感染易感的动物的保护性免疫。 优选的氨基酸序列选自1）包含选自SEQ ID No：1-455，SEQ ID No 466或由SEQ ID No：456编码的多肽的序列的SEQ ID NO：456所示的多肽 ID号：457或SEQ ID No：466; 2）与序列同源性至少85％，更优选至少约90％的序列同源性，更优选至少约95％的序列同源性，甚至更优选至少约97％的序列同源性的任何多肽，甚至更优选在 至少约98％的序列同源性，甚至更优选至少约99％与1）多肽的序列同源性; 3）1）和/或2）的多肽的任何免疫原性部分和/或2）4）3）的免疫原性部分，其包含至少300,290,280,270,260,250,240,230,220,210,2200， 190，180，170，160，150，140，130，120，110，100，90，80，70，60，50，45，40，35，30，25，20，18，15，13， 或最优选9个连续氨基酸，包括在SEQ ID No：1-455，SEQ ID No：456或由SEQ ID No：457或SEQ ID No：466编码的氨基酸序列中; 和/或5）由编码包含SEQ ID No：1-455或SEQ ID No：466的序列的肽的DNA编码的多肽。因此，编码这些蛋白质或蛋白质本身的核酸序列 包括在疫苗组合物中，以及兽医学可接受的载体并且施用于有需要的动物。

    Porcine reproductive and respiratory syndrome isolates and methods of use
    5.
    发明申请
    Porcine reproductive and respiratory syndrome isolates and methods of use 审中-公开
    猪繁殖与呼吸综合征分离株及其使用方法

    公开(公告)号：US20060063151A1

    公开(公告)日：2006-03-23

    申请号：US11230723

    申请日：2005-09-20

    申请人： Michael Roof ,  Eric Vaughn ,  Wesley Johnson

    发明人： Michael Roof ,  Eric Vaughn ,  Wesley Johnson

    IPC分类号： C12Q1/70 ,  C12Q1/68

    CPC分类号： C12N7/00 ,  C12N2770/10031 ,  C12Q1/701

    摘要： A method of predicting the virulence of a new or uncharacterized PRRS virus isolate is provided wherein the isolate is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus isolate of known virulence, as a measure of the virulence of the new or uncharacterized isolate. Additionally, a method of selecting an isolate for inclusion in an immunogenic composition based on the predicted virulence is also provided, together with compositions incorporating attenuated forms of viruses predicted to be virulent.

    摘要翻译： 提供了一种预测新的或未表征的PRRS病毒分离物的毒力的方法，其中所述分离物被注射到猪中并允许复制约3-15天的时间。 在此期间，确定病毒生长率和/或病毒血症的大小，并将该数据与已知毒力的PRRS病毒分离株的相应生长速率和/或病毒血症量进行比较，作为毒力 新的或非特异性的分离物。 此外，还提供了基于预测的毒力选择包含在免疫原性组合物中的分离物的方法以及预测为有毒性的减毒病毒形式的组合物。

    INFLUENZA H5 VACCINES
    6.
    发明申请
    INFLUENZA H5 VACCINES 审中-公开

    公开(公告)号：US20140199337A1

    公开(公告)日：2014-07-17

    申请号：US14238796

    申请日：2012-08-15

    申请人： Mauricio Realpe-Quintero ,  Paulino Carlos Gonzalez-Hernandez ,  Eric Vaughn

    发明人： Mauricio Realpe-Quintero ,  Paulino Carlos Gonzalez-Hernandez ,  Eric Vaughn

    IPC分类号： A61K39/145 ,  A61K39/17 ,  C07K14/005

    摘要： The present invention is based on the surprising finding that H5 protein of clade 1 H5N1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with H5N1 HA. In one aspect, the invention is thus directed to H5 protein of clade 1 H5N1 virus for use in a method of treating or preventing infections with H5N1 virus of a different clade, namely of a clade different from clade 1 or from any clade with the exception of clade 1, respectively.

    摘要翻译： 本发明基于惊人的发现，即进化枝1 H5N1的H5蛋白特别是通过单次疫苗接种诱导具有H5N1HA的流感病毒的交叉进化枝保护性免疫应答。 一方面，本发明涉及到H5N1进化枝H5蛋白的H5蛋白，用于治疗或预防不同进化枝的H5N1病毒感染的方法，即与进化枝1不同的进化枝或异常的任何进化枝 的进化枝1。

    Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same
    9.
    发明申请
    Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same 有权
    欧氏结核杆菌血吸虫嗜血杆菌疫苗及其使用方法

    公开(公告)号：US20060093622A1

    公开(公告)日：2006-05-04

    申请号：US10975702

    申请日：2004-10-28

    申请人： John Swart ,  Eric Vaughn ,  Karen Freking ,  Michael Roof ,  Phillip Hayes ,  Reid Phillips

    发明人： John Swart ,  Eric Vaughn ,  Karen Freking ,  Michael Roof ,  Phillip Hayes ,  Reid Phillips

    IPC分类号： A61K39/116

    CPC分类号： A61K39/102 ,  A61K39/0241 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55566

    摘要： The present invention provides a composition and an improved single dose vaccine against E. rhusiopathiae and an improved single dose vaccine against E. rhusiopathiae and H. parasuis which provides one or more of the following: 1) confers effective immunity against E. rhusiopathiae and/or H. parasuis; 2) decreases the risk of developing clinical signs of E. rhusiopathiae and/or H. parasuis infection; 3) induces an immune response against E. rhusiopathiae and/or H. parasuis; and 4) has a DOI against E. rhusiopathiae and/or H. parasuis of at least four months. The composition or E. rhusiopathiae vaccine as well as the combined E. rhusiopathiae-H. parasuis composition or vaccine each includes a bacterial component of inactivated E. rhusiopathiae bacteria and a suitable adjuvant. The combined E. rhusiopathiae-H. parasuis composition or vaccine further includes an amount of H. parasuis antigen. The vaccines can be administered to animals in any conventional manner. The amount of the dose for intramuscular administration is preferably less than 5 ml. The amount of E. rhusiopathiae and/or H. parasuis antigen in each dose should be enough to induce an immune response in the animal receiving the vaccine or composition and will preferably confer effective immunity against and decrease the risk of developing clinical signs resulting from E. rhusiopathiae and/or H. parasuis infection for a suitable duration of immunity.

    摘要翻译： 本发明提供组合物和改进的针对埃氏杆菌病的单一剂量疫苗和针对针对埃希氏杆菌和副猪嗜血杆菌的改进的单剂量疫苗，其提供以下一种或多种：1）赋予针对E.杆菌病和/ 或副猪嗜血菌 2）降低发生脑炎病毒和/或副猪嗜血杆菌感染的临床症状的风险; 3）诱导针对埃氏杆菌和/或副猪嗜血杆菌的免疫应答; 和4）具有至少四个月的针对E.hathiopathiae和/或副猪嗜血杆菌的DOI。 组合物或E.杆菌病疫苗以及组合的脑炎病毒H。 副产物组合物或疫苗各自包括灭活的肠球菌属细菌的细菌组分和合适的佐剂。 合并的脑炎病毒H。 副产物组成或疫苗还包括一定量的副猪嗜血杆菌抗原。 疫苗可以以任何常规方式施用于动物。 肌内给药的剂量优选小于5ml。 每种剂量的肠球菌和/或副猪嗜血杆菌抗原的量应足以在接受疫苗或组合物的动物中诱导免疫应答，并且优选地赋予有效的免疫力并降低由E引起的临床体征的风险 rhusiopathiae和/或副猪嗜血杆菌感染，具有合适的免疫持续时间。